Clinical Trial

Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients

SHANGHAI, China, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

8 months ago

ExCellThera to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference and to Participate in Upcoming Investor Conferences

MONTREAL, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell therapies, announced today…

8 months ago

XORTX Welcomes New Member to the Board of Directors

CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…

8 months ago

Fortrea to Present at the 42nd Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced…

8 months ago

TechImmune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- TechImmune, LLC., a biotechnology company developing a broad-spectrum, next generation coronavirus…

8 months ago

Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang,…

8 months ago

Angle PLC – Contract announcement with Eisai Inc.

Pilot study for ANGLE's Portrait HER2 assay in Phase II study of HER2 targeting antibody-drug conjugate, BB-1701GUILDFORD, SURREY / ACCESSWIRE…

8 months ago

Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program

Cell BioEngines to Leverage Miltenyi’s Expertise and Proven Platforms to Develop and Manufacture Hematopoietic Stem Cell Transplantation (HSCT) Product Cell…

8 months ago

MedMira Reports First Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / December 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for…

8 months ago

Hemostemix Clarifies its October 3, 2023 News Release

Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

8 months ago